Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immune 1(TM) complexed PSA assay

International Journal of Biological Markers

Volumn 14, Issue 2, 1999, Pages 73-83

  Allard, W J ^a   Cheli, C D ^a   Morris, D L ^a   Goldblatt, J ^a   Pierre, Y ^a   Kish, L ^a   Chen, Y ^a   Dai, J ^a   Lvessella, R L ^a   Chan, D W ^a   Schwartz, M K ^a   Zhou, Z ^a   Yeung, K K ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Automation; Immunoassays; Performance; Prostate cancer; Prostate specific antigen; PSA ACT; Tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVALUATION; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PROSTATE CANCER; RETROSPECTIVE STUDY; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 0033038762     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)